Contemporary Oncology®: Biomarkers, Pathways, and Targeted Therapies® - May 2022 | Contemporary Oncology®

Emerging Targeted Therapies Continue to Shift Paradigm in EGFR Exon 20–Mutated NSCLC

May 12, 2022

Edward Kim, MD, MBA, discussed the facets of each presentation from the meeting, featuring other emerging targeted therapies in NSCLC, biomarker testing in the space, frontline immunotherapy in NSCLC, and the current management of small cell lung cancer.

HER2 Expression Is a Key Determinant of Trastuzumab Deruxtecan Activity

May 08, 2022

HER2 expression appeared to be a significant predictor for response to fam-trastuzumab deruxtecan-nxki, according to findings from a biomarker analysis of patients with metastatic breast cancer in the phase 2 DAISY trial.

Biomarker Testing Will Fuel Next Wave of Treatment Innovations in Breast Cancer

May 01, 2022

Christos Vaklavas, MD, discusses the increasing emphasis on investigating tumor biology in breast cancer, plus the evolving treatment landscapes in HER2-positive breast cancer, hormone receptor–positive, HER2-negative breast cancer, and triple-negative breast cancer.